Alliances
Galapagos NV and MorphoSys AG announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the worldwide, exclusive license agreement with Novartis Pharma AG, entered into on July 19, 2018, for the development and commercialization of their joint program MOR106 (the Collaboration Agreement).
Vision Research, a leading manufacturer of digital high-speed imaging systems, is pleased to announce a partnership with Love High Speed that grants exclusive rights to rent the new Phantom® v2640 Onyx within Europe and the Middle East.
Octapharma USA Partners with GutMonkey To Provide Hemophilia Patients Life-Changing Adventure Experience
In many ways, licensing deals have become part of the life’s blood of the biopharma industry. According to a new report released by the global consulting firm Charles River Associates (CRA), approximately 75 percent of all new biologics and small molecules launched in the United States were not discovered by the company or entity that commercialized the product.
CURE grants cannabis leader rights to its proprietary drug delivery technology in markets around the world
Adaptimmune Therapeutics plc today announced that it has entered into a definitive agreement with Matrix Capital Management Company
IRBM signs collaboration agreement with Merck & Co., Inc, Kenilworth, NJ, USA to advance peptide therapeutics
Oncolytics Biotech® Inc. today announced that it has entered into a Master Clinical Supply Agreement (Agreement) with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq®) for use in the company’s clinical development program.
Oncolytics Biotech® Inc. today announced a clinical collaboration with SOLTI, an academic research group dedicated to clinical and translational research in breast cancer.
Partnership combines Intellegens’ proprietary AI technology withOptibrium’s expertise in predictive modelling and compound design
PRESS RELEASES